臨床泌尿器科74巻10号

2020年09月発行

特集 令和最新版! 泌尿器がん薬物療法―手元に置きたい心強い一冊

〈各論〉

泌尿器科領域希少癌（陰茎癌・副腎癌・尿膜管癌）の薬物療法

著者： 浦崎哲也¹ 高橋俊二¹

所属機関： ¹がん研究会有明病院総合腫瘍科

ページ範囲：P.790 - P.800

文献概要

▶ポイント

・泌尿器科領域の希少癌に対する現在の標準的な治療について理解し，現在進行中の臨床試験の動向をフォローする．

・がん遺伝子パネル検査から組織非依存性がん治療法につなげていくことは，治療の重要な選択肢の1つである．

参考文献

1） Corral DA, et al : Combination Chemotherapy for Metastasis or Locally Advanced Genitourinary Squamous Cell Carcinoma : A Phase II Study of Methotrexate, Cisplatin and Bleomycin. J Urol 160 : 1770-1774, 1998

2） Haas GP, et al : Cisplatin, Methotrexate and Bleomycin for the Treatment of Carcinoma of the Penis : A Southwest Oncology Group Study. J Urol 161 : 1823-1825, 1999

3） Bermejo C, et al : Neoadjuvant Chemotherapy Followed by Aggressive Surgical Consolidation for Metastatic Penile Squamous Cell Carcinoma. J Urol 177 : 1335-1338, 2007

4） Pagliaro LC, et al : Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer : A Phase II Study. J Clin Oncol 28 : 3851-3857, 2010

5） Xu J, et al : Neoadjuvant Docetaxel, Cisplatin and Ifosfamide （ITP） Combination Chemotherapy for Treating Penile Squamous Cell Carcinoma Patients with Terminal Lymph Node Metastasis. BMC Cancer 19 : 625, 2019

6） Di Lorenzo G, et al : Cisplatin and 5-Fluorouracil in Inoperable, Stage IV Squamous Cell Carcinoma of the Penis. BJU Int 110 : E661-666, 2012

7） Carthon BC, et al : Epidermal Growth Factor Receptor-Targeted Therapy in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis. BJU Int 113 : 871-877, 2014

8） Nicholson S, et al : Phase II Trial of Docetaxel, Cisplatin and 5FU Chemotherapy in Locally Advanced and Metastatic Penis Cancer （CRUK/09/001）. Br J Cancer 109 : 2554-2559, 2013

9） Zhang S, et al : Phase II Study of Docetaxel, Cisplatin, and Fluorouracil in Patients with Distantly Metastatic Penile Cancer as First-Line Chemotherapy. Oncotarget 6 : 32212-32219, 2015

10） Djajadiningrat RS, et al : Neoadjuvant Taxane-Based Combination Chemotherapy in Patients with Advanced Penile Cancer. Clin Genitourin Cancer 13 : 44-49, 2015

11） Challapalli A, et al : A Phase II Trial of Cabazitaxel as Second Line Chemotherapy in Relapsed Locally Advanced and/or Metastatic Carcinoma of the Penis. J Int Med Res 47 : 4664-4672, 2019

12） Bilimoria KY, et al : Adrenocortical Carcinoma in the United States : Treatment Utilization and Prognostic Factors. Cancer 113 : 3130-3136, 2008

13） Fassnacht M, et al : Epidemiology of Adrenocortical Carcinoma. In : Hammer GD, et al （eds） : Adrenocortical Carcinoma : Basic Science and Clinical Concepts. pp23-29, Springer, New York, 2010

14） Avien G, et al : Clinical and Biological Features in the Prognosis of Adrenocortical Cancer : Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. J Clin Endocrinol Metab 91 : 2650-2655, 2006

15） Berruti A, et al : Adrenal cancer : ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol 23 : 131-138, 2012

16） Fassnacht M, et al : European Society of Endocrinology Clinical Practice Guidelines on the management of Adrenocortical Carcinoma in Adults, in Collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179 : G1-G46, 2018

17） Fassnacht M, et al : Limited Prognostic Value of the 2004 International Union Against Cancer Staging Classification for Adrenocortical Carcinoma : Proposal for a Revised TNM Classification. Cancer 115 : 243-250, 2009

18） Fassnacht M, et al : Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med 366 : 2189-2197, 2012

19） Sperone P, et al : Gemcitabine Plus Metronomic 5-Fluorouracil or Capecitabine as a Second-/Third-Line Chemotherapy in Advanced Adrenocortical Carcinoma : A Multicenter Phase II Study. Endocr Relat Cancer 17 : 445-453, 2010

20） Henning JEK, et al : Gemcitabine-based Chemotherapy in Adrenocortical Carcinoma : A Multicentric Study on Efficacy and Predictive Factors. J Clin Endocrinol Metab 102 : 4323-4332, 2017

21） Megerle F, et al : Advanced Adrenocortical Carcinoma―What to Do when First-Line Therapy Fails? Exp Clin Endocrinol Diabetes 127 : 109-116, 2019

22） Kroiss M, et al : Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Horm Cancer 7 : 2011-2018, 2016

23） Kroiss M, et al : Treatment of Refractory Adrenocortical Carcinoma with Thalidomide : Analysis of 27 Patients from the European Network for the Study of Adrenal Tumors Registry. Exp Clin Endocrinol Diabetes 127 : 578-584, 2019

24） Haluska P, et al : Safety, Tolerability, and Pharmacokinetics of the Anti-IGF-1R Monoclonal Antibody Figitumumab in Patients with Refractory Adrenocortical Carcinoma. Cancer Chemother Pharmacol 65 : 765-773, 2010

25） Weigel B, et al : Phase 2 Trial of Cixutumumab in Children, Adolescents and Young Adults with Refractory Solid Tumors : A Report from the Children's Oncology Group. Pediatr Blood Cancer 61 : 452-456, 2014

26） Lerario AM, et al : The Combination of Insulin-Like Growth Factor Receptor 1 （IGF1R） Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma : A Multi-institutional NCI-Sponsored Trial. Horm Cancer 5 : 232-239, 2014

27） Fassnacht M, et al : Linsitinib （OSI-906） Versus Placebo for Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma : A Double-Blind, Randomised, Phase 3 Study. Lancet Oncol 16 : 426-435, 2015

28） Raj N, et al : PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol 38 : 71-80, 2020

29） Kerkhofs TM, et al : Developing Treatment for Adrenocortical Carcinoma. Endocr Relat Cancer 22 : R325-338, 2015

30） Creemers SG, et al : Future Directions in the Diagnosis and Medical Treatment of Adrenocortical Carcinoma. Endocr Relat Cancer 23 : 43-69, 2016

31） Averbuch SD, et al : Malignant Pheochromocytoma : Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine. Ann Intern Med 109 : 267-273, 1988

32） Huang H, et al : Treatment of Malignant Pheochromocytoma/Paraganglioma with Cyclophosphamide, Vincristine, and Dacarbazine : Recommendation from a 22-Year Follow-Up of 18 Patients. Cancer 113 : 2020-2028, 2008

33） Tanabe A, et al : Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma. Horm Cancer 4 : 103-110, 2013

34） Gonias S, et al : Phase II Study of High-Dose ［131I］ Metaiodobenzylguanidine Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma. J Clin Oncol 27 : 4162-4168, 2009

35） Pryma DA, et al : Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med 60 : 623-630, 2019

36） O'kane GM, et al : A Phase 2 Trial of Sunitinib in Patients with Progressive Paraganglioma or Pheochromocytoma : The SNIPP Trial. Br J Cancer 120 : 1113-1119, 2019

37） Jasim S, et al : Phase II Trial of Pazopanib in Advanced/Progressive Malignant Pheochromocytoma and Paraganglioma. Endocrine 57 : 220-225, 2017

38） Hadoux J, et al : SDHB Mutations are Associated with Response to Temozolomide in Patients with Metastatic Pheochromocytoma or Paraganglioma. Int J Cancer 135 : 2711-2720, 2014

39） Hadoux J, et al : Interferon-Alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Horm Cancer 8 : 330-337, 2017

40） Lowery AJ, et al : Molecular and Therapeutic Advances in the Diagnosis and Management of Malignant Pheochromocytomas and Paragangliomas. Oncologist 18 : 391-407, 2013

41） Baudin E, et al : Therapy of Endocrine Disease : Treatment of Malignant Pheochromocytoma and Paraganglioma. Eur J Endocrinol 171 : R111-122, 2014

42） Sheldon CA, et al : Malignant Urachal Lesions. J Urol 131 : 1-8, 1984

43） Ashley RA, et al : Urachal Carcinoma : Clinicopathologic Features and Long-Term Outcomes of an Aggressive Malignancy. Cancer 107 : 712-720, 2006

44） Bruins HM, et al : The Clinical Epidemiology of Urachal Carcinoma : Results of a Large, Population Based Study. J Urol 188 : 1102-1107, 2012

45） Yu B, et al : Neoadjuvant Chemotherapy for Primary Adenocarcinomas of the Urinary Bladder : A Single-Site Experience. BMC Urol 15 : 3, 2015

46） Yanagihara Y, et al : Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer. Chemotherapy 59 : 402-406, 2013

47） Kanamaru T, et al : A Case of Metastatic Urachal Carcinoma Treated with FOLFIRI （Irinotecan and 5-Fluorouracil/Leucovorin） Plus Bevacizumab. Urol Case Rep 3 : 9-11, 2015

48） Hayashi T, et al : Clinical Outcome of Urachal Cancer in Japanese Patients. Int J Clin Oncol 21 : 133-138, 2016

49） Siefker-Radtke A, et al : Urachal Carcinoma : Surgical and Chemotherapeutic Options. Expert Rev Anticancer Ther 6 : 1715-1721, 2006

50） Collazo-Lorduy A, et al : Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epedermal Growth Factor Inhibition. Eur Urol 70 : 771-775, 2016

51） Siefker-Radtke AO, et al : Multimodality Management of Urachal Carcinoma : The M.D. Anderson Cancer Center Experience. J Urol 169 : 1295-1298, 2003

52） Urasaki T, et al : Cisplatin and S-1 for Urachal Carcinoma : A Single-Institution Case Series. IJU Case Rep 2 : 150-154, 2019

53） Módos O, et al : Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA Genes in Urachal Carcinoma : Occurrence and Prognostic Significance. Oncotarget 7 : 39293-39301, 2016